ASC’s lead product, Chondrofelt, (a medical device) is intended to repair articular cartilage defects. These defects are either caused by trauma or osteoarthritis. Chondrofelt will be used in conjunction with the surgical procedure known as microfracture. In microfracture, holes are punctured in the base of the defect into the underlying bone, with the aim of recruiting resident (autologous) stem cells from the bone marrow. Chondofelt will be placed in the defect to capture these stem cells to enhance repair. Chondrofelt will also be used with autologous stem cells harvested from the patient’s bone marrow. In this two step procedure, bone marrow will be harvested from the patient and the stem cell population enriched. The cells will then be incubated in Chondrofelt for 1-2 hours and then implanted in the cartilage defect of the patient.
Chondrofelt will ensure that the patient’s stem cells reach the defect and remain in the defect, enhancing repair. There are approximately 500,000 cartilage repair operations performed in the United States annually.